uniQure Crescita futura
Future criteri di controllo 2/6
Si prevede che uniQure aumenterà gli utili e i ricavi rispettivamente del 17.1% e 35.8% all'anno, mentre si prevede che l'EPS crescerà del 21.3% all'anno.
Informazioni chiave
17.1%
Tasso di crescita degli utili
21.3%
Tasso di crescita dell'EPS
| Biotechs crescita degli utili | 28.3% |
| Tasso di crescita dei ricavi | 35.8% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Good |
| Ultimo aggiornamento | 07 Nov 2024 |
Aggiornamenti recenti sulla crescita futura
uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 03
Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts
Mar 03Recent updates
uniQure's Yellow Flags: Early-Stage Gene Therapies Amid Restructuring
Oct 21uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity
Aug 06uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 03uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts
Jul 09Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts
Mar 03uniQure: The Valuation Got More Attractive
Feb 01Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding
Jan 17A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)
Dec 15Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)
Aug 27Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be
Aug 06Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money
Aug 02uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough
Jul 02Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher
Jun 28uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
May 14Is uniQure (NASDAQ:QURE) Using Debt Sensibly?
Apr 11News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat
Mar 01Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?
Dec 09uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion
Sep 21uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch
Aug 30uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
Aug 14uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy
Aug 08These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely
Jun 08uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
May 04uniQure N.V.: Worth A Look Based On Hemophilia B Marketing Applications
Apr 08We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings
Mar 04The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically
Feb 27Is uniQure (NASDAQ:QURE) A Risky Investment?
Feb 23uniQure: Betting On Hemophilia-B Cure
Jan 18Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2026 | 93 | -126 | -80 | -71 | 10 |
| 12/31/2025 | 41 | -141 | -53 | -83 | 13 |
| 12/31/2024 | 39 | -194 | -157 | -152 | 13 |
| 9/30/2024 | 29 | -240 | -185 | -179 | N/A |
| 6/30/2024 | 28 | -285 | -111 | -104 | N/A |
| 3/31/2024 | 19 | -297 | -135 | -128 | N/A |
| 12/31/2023 | 16 | -308 | -153 | -146 | N/A |
| 9/30/2023 | 112 | -228 | -161 | -151 | N/A |
| 6/30/2023 | 112 | -187 | -251 | -239 | N/A |
| 3/31/2023 | 110 | -157 | -214 | -198 | N/A |
| 12/31/2022 | 106 | -127 | -163 | -145 | N/A |
| 9/30/2022 | 61 | -125 | -154 | -137 | N/A |
| 6/30/2022 | 62 | -114 | -149 | -129 | N/A |
| 3/31/2022 | 525 | 324 | 286 | 304 | N/A |
| 12/31/2021 | 524 | 330 | 271 | 288 | N/A |
| 9/30/2021 | 500 | 321 | 281 | 298 | N/A |
| 6/30/2021 | 500 | 303 | 292 | 303 | N/A |
| 3/31/2021 | 38 | -139 | -154 | -143 | N/A |
| 12/31/2020 | 38 | -125 | -144 | -135 | N/A |
| 9/30/2020 | 6 | -166 | -132 | -124 | N/A |
| 6/30/2020 | 5 | -136 | -120 | -111 | N/A |
| 3/31/2020 | 6 | -124 | -114 | -105 | N/A |
| 12/31/2019 | 7 | -124 | -105 | -99 | N/A |
| 9/30/2019 | 6 | -105 | -96 | -91 | N/A |
| 6/30/2019 | 8 | -103 | -93 | -89 | N/A |
| 3/31/2019 | 9 | -92 | -86 | -81 | N/A |
| 12/31/2018 | 11 | -83 | -80 | -76 | N/A |
| 9/30/2018 | 12 | -90 | -81 | -76 | N/A |
| 6/30/2018 | 11 | -78 | N/A | -71 | N/A |
| 3/31/2018 | 13 | -78 | N/A | -74 | N/A |
| 12/31/2017 | 13 | -79 | N/A | -64 | N/A |
| 9/30/2017 | 20 | -67 | N/A | -62 | N/A |
| 6/30/2017 | 25 | -72 | N/A | -65 | N/A |
| 3/31/2017 | 24 | -71 | N/A | -68 | N/A |
| 12/31/2016 | 25 | -73 | N/A | -72 | N/A |
| 9/30/2016 | 20 | -76 | N/A | -81 | N/A |
| 6/30/2016 | 16 | -90 | N/A | -62 | N/A |
| 3/31/2016 | 14 | -90 | N/A | 5 | N/A |
| 12/31/2015 | 11 | -82 | N/A | 7 | N/A |
| 9/30/2015 | 8 | -76 | N/A | 22 | N/A |
| 6/30/2015 | 6 | -58 | N/A | 13 | N/A |
| 3/31/2015 | 5 | -45 | N/A | -35 | N/A |
| 12/31/2014 | 6 | -50 | N/A | -37 | N/A |
| 9/30/2014 | 5 | -41 | N/A | -29 | N/A |
| 6/30/2014 | 6 | -42 | N/A | -6 | N/A |
| 3/31/2014 | 6 | -41 | N/A | -7 | N/A |
| 12/31/2013 | 4 | -37 | N/A | -6 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che QURE rimarrà non redditizia nei prossimi 3 anni.
Guadagni vs Mercato: Si prevede che QURE rimarrà non redditizia nei prossimi 3 anni.
Guadagni ad alta crescita: Si prevede che QURE rimarrà non redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di QURE ( 35.8% all'anno) crescerà più rapidamente del mercato US ( 8.9% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di QURE ( 35.8% all'anno) crescerà più rapidamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di QURE è previsto essere elevato tra 3 anni